Ser587

Site Information
tAGHRANsPsLFGtE SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 457025

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 13 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ) , mutation of modification site ( 13 ) , phospho-antibody ( 13 ) , western blotting ( 13 )
Disease tissue studied:	breast cancer ( 6 , 7 , 16 ) , breast ductal carcinoma ( 6 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 6 ) , cervical cancer ( 33 ) , cervical adenocarcinoma ( 33 ) , leukemia ( 17 ) , acute myelogenous leukemia ( 17 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 15 , 17 ) , acute megakaryoblastic leukemia (M7) ( 15 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 15 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 15 ) , acute myeloblastic leukemia, without maturation (M1) ( 15 ) , lung cancer ( 9 , 16 , 26 , 29 ) , non-small cell lung cancer ( 16 ) , non-small cell lung adenocarcinoma ( 9 , 26 ) , lymphoma ( 8 ) , B cell lymphoma ( 15 ) , Burkitt's lymphoma ( 8 ) , non-Hodgkin's lymphoma ( 15 ) , follicular lymphoma ( 8 ) , mantle cell lymphoma ( 8 ) , ovarian cancer ( 6 ) , multiple myeloma ( 15 ) , melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:	'muscle, skeletal' ( 35 ) , 'stem, embryonic' ( 36 ) , 293 (epithelial) ( 5 , 13 ) , A498 (renal) ( 31 ) , A549 (pulmonary) ( 10 ) , AML-193 (monocyte) ( 15 , 17 ) , BJAB (B lymphocyte) ( 8 ) , breast ( 2 , 6 ) , BT-20 (breast cell) ( 16 ) , BT-549 (breast cell) ( 16 ) , Calu 6 (pulmonary) ( 16 ) , CL1-0 (pulmonary) ( 29 ) , CL1-1 (pulmonary) ( 29 ) , CL1-2 (pulmonary) ( 29 ) , CL1-5 (pulmonary) ( 29 ) , CMK (megakaryoblast) ( 15 ) , CTS (myeloid) ( 15 ) , DOHH2 ('B lymphocyte, precursor') ( 15 ) , FL-18 (B lymphocyte) ( 8 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 18 ) , Flp-In T-Rex-293 (epithelial) ( 18 ) , GM00130 (B lymphocyte) ( 30 ) , H2009 (pulmonary) ( 16 ) , H2077 (pulmonary) ( 16 ) , H2887 (pulmonary) ( 16 ) , H322M (pulmonary) ( 16 ) , HCC1359 (pulmonary) ( 16 ) , HCC1937 (breast cell) ( 16 ) , HCC2279 (pulmonary) ( 16 ) , HCC366 (pulmonary) ( 16 ) , HCC4006 (pulmonary) ( 16 ) , HCC78 (pulmonary) ( 16 ) , HCC827 (pulmonary) ( 16 ) , HEL (erythroid) ( 15 , 17 ) , HeLa (cervical) ( 1 , 4 , 14 , 27 , 28 , 34 , 38 , 39 , 40 ) , HeLa S3 (cervical) ( 33 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 7 ) , HMLER ('stem, breast cancer') ( 7 ) , HOP62 (pulmonary) ( 16 ) , HT-29 (intestinal) ( 42 ) , Jurkat (T lymphocyte) ( 11 , 20 , 21 , 22 , 23 , 24 , 25 , 41 ) , K562 (erythroid) ( 14 ) , Kasumi-1 (myeloid) ( 15 ) , KG-1 (myeloid) ( 15 ) , LCLC-103H (pulmonary) ( 16 ) , leukocyte-blood ( 32 ) , LOU-NH91 (squamous) ( 16 ) , lung ( 9 ) , MCF-7 (breast cell) ( 16 ) , MDA-MB-231 (breast cell) ( 16 ) , MDA-MB-468 (breast cell) ( 16 ) , MV4-11 (macrophage) ( 15 ) , NCEB-1 (B lymphocyte) ( 8 ) , NCI-H1395 (pulmonary) ( 16 ) , NCI-H1568 (pulmonary) ( 16 ) , NCI-H157 (pulmonary) ( 16 ) , NCI-H1648 (pulmonary) ( 16 ) , NCI-H1666 (pulmonary) ( 16 ) , NCI-H2030 (pulmonary) ( 16 ) , NCI-H2172 (pulmonary) ( 16 ) , NCI-H322 (pulmonary) ( 16 ) , NCI-H460 (pulmonary) ( 16 , 37 ) , NCI-H520 (squamous) ( 16 ) , NCI-H647 (pulmonary) ( 16 ) , OPM-2 (plasma cell) ( 15 ) , ovary ( 6 ) , P31/FUJ (erythroid) ( 15 ) , PC9 (pulmonary) ( 16 ) , Raji (B lymphocyte) ( 8 ) , REC-1 (B lymphocyte) ( 8 ) , RL ('B lymphocyte, precursor') ( 15 ) , RPMI-8266 (plasma cell) ( 15 ) , SU-DHL-6 (B lymphocyte) ( 15 ) , U-1810 (pulmonary) [EFNB3 (human), knockdown] ( 26 ) , U-1810 (pulmonary) ( 26 ) , U266 (plasma cell) ( 15 ) , WM239A (melanocyte) ( 3 )

Upstream Regulation
Regulatory protein:	Akt1 (human) ( 13 )
Treatments:	CK59 ( 13 ) , EGF ( 13 ) , ischemia ( 6 ) , metastatic potential ( 29 ) , phorbol_ester ( 13 ) , SB202190 ( 34 ) , vemurafenib ( 3 )

Downstream Regulation
Effects of modification on SH3KBP1:	molecular association, regulation ( 13 )
Inhibit interaction with:	DAB1 (human) ( 13 )

References
1	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
4	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
5	Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54 24965592 Curated Info
6	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
7	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
8	Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42 24667141 Curated Info
9	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
10	Kim JY, et al. (2013) Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 110, 12414-9 23836654 Curated Info
11	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
12	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
13	Bior BK, Ballif BA (2013) Dab1 stabilizes its interaction with Cin85 by suppressing Cin85 phosphorylation at serine 587. FEBS Lett 587, 60-6 23178720 Curated Info
14	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
15	Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37 23628362 Curated Info
16	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
17	Alcolea MP, et al. (2012) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 11, 453-66 22547687 Curated Info
18	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
19	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
20	Mulhern D (2011) CST Curation Set: 12699; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
21	Mulhern D (2011) CST Curation Set: 12701; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
22	Mulhern D (2011) CST Curation Set: 12702; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
23	Mulhern D (2011) CST Curation Set: 12572; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
24	Mulhern D (2011) CST Curation Set: 12569; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
25	Mulhern D (2011) CST Curation Set: 12571; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSPX(I/L/M/V) Curated Info
26	Ståhl S, et al. (2011) Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor. J Proteome Res 10, 2566-78 21413766 Curated Info
27	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
28	Hegemann B, et al. (2011) Systematic phosphorylation analysis of human mitotic protein complexes. Sci Signal 4, rs12 22067460 Curated Info
29	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
30	Bennetzen MV, et al. (2010) Site-specific phosphorylation dynamics of the nuclear proteome during the DNA damage response. Mol Cell Proteomics 9, 1314-23 20164059 Curated Info
31	Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62 20071362 Curated Info
32	Raijmakers R, et al. (2010) Exploring the human leukocyte phosphoproteome using a microfluidic reversed-phase-TiO2-reversed-phase high-performance liquid chromatography phosphochip coupled to a quadrupole time-of-flight mass spectrometer. Anal Chem 82, 824-32 20058876 Curated Info
33	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
34	Pan C, Olsen JV, Daub H, Mann M (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics 8, 2796-808 19651622 Curated Info
35	Højlund K, et al. (2009) In vivo phosphoproteome of human skeletal muscle revealed by phosphopeptide enrichment and HPLC-ESI-MS/MS. J Proteome Res 8, 4954-65 19764811 Curated Info
36	Brill LM, et al. (2009) Phosphoproteomic analysis of human embryonic stem cells. Cell Stem Cell 5, 204-13 19664994 Curated Info
37	Nagano K, et al. (2009) Phosphoproteomic analysis of distinct tumor cell lines in response to nocodazole treatment. Proteomics 9, 2861-74 19415658 Curated Info
38	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
39	Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7 18669648 Curated Info
40	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
41	Stokes M (2008) CST Curation Set: 3886; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
42	Kim JE, Tannenbaum SR, White FM (2005) Global phosphoproteome of HT-29 human colon adenocarcinoma cells. J Proteome Res 4, 1339-46 16083285 Curated Info